Perspective

Split Viewer

Blood Res 2013; 48(2):

Published online June 25, 2013

https://doi.org/10.5045/br.2013.48.2.72

© The Korean Society of Hematology

Plerixafor use for peripheral blood stem cell mobilization in Korea

Seok Jin Kim, M.D. Ph.D.1, Dok Hyun Yoon, M.D. Ph.D.2, Deok-Hwan Yang, M.D. Ph.D.3, Hyeon Seok Eom, M.D. Ph.D.4, Seok Goo Cho, M.D. Ph.D.5, Sung-Soo Yoon, M.D. Ph.D.6, Jae Hoon Lee, M.D. Ph.D.7, Won Seog Kim, M.D. Ph.D.1, and Cheolwon Suh, M.D. Ph.D.2

1Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

2Department of Oncology, Asan Medical Center, University of Ulsan, Seoul, Korea.

3Department of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, Korea.

4Hematologic Malignancy Branch, National Cancer Center, Ilsan, Korea.

5Department of Internal Medicine, St. Mary Hospital, The Catholic University of Korea, Seoul, Korea.

6Department of Internal Medicine, Seoul National University Hospiltal, Seoul, Korea.

7Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

REFERENCES

  1. Weaver, CH, Hazelton, B, Birch, R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood, 1995;86;3961-3969.
    Pubmed
  2. Gordan, LN, Sugrue, MW, Lynch, JW, et al. Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma, 2003;44;815-820.
    Pubmed
  3. DiPersio, JF, Micallef, IN, Stiff, PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol, 2009;27;4767-4773.
    Pubmed
  4. Olivieri, A, Marchetti, M, Lemoli, R, et al. Proposed definition of poor mobilizer in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo Italiano-Trapianto di Midollo Osseo. Bone Marrow Transplant, 2012;47;342-351.
    Pubmed
  5. Basak, GW, Jaksic, O, Koristek, Z, et al. Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization. Am J Hematol, 2011;86;550-553.
    Pubmed

Article

Perspective

Blood Res 2013; 48(2): 72-73

Published online June 25, 2013 https://doi.org/10.5045/br.2013.48.2.72

Copyright © The Korean Society of Hematology.

Plerixafor use for peripheral blood stem cell mobilization in Korea

Seok Jin Kim, M.D. Ph.D.1, Dok Hyun Yoon, M.D. Ph.D.2, Deok-Hwan Yang, M.D. Ph.D.3, Hyeon Seok Eom, M.D. Ph.D.4, Seok Goo Cho, M.D. Ph.D.5, Sung-Soo Yoon, M.D. Ph.D.6, Jae Hoon Lee, M.D. Ph.D.7, Won Seog Kim, M.D. Ph.D.1, and Cheolwon Suh, M.D. Ph.D.2

1Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

2Department of Oncology, Asan Medical Center, University of Ulsan, Seoul, Korea.

3Department of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, Korea.

4Hematologic Malignancy Branch, National Cancer Center, Ilsan, Korea.

5Department of Internal Medicine, St. Mary Hospital, The Catholic University of Korea, Seoul, Korea.

6Department of Internal Medicine, Seoul National University Hospiltal, Seoul, Korea.

7Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

    References

    1. Weaver, CH, Hazelton, B, Birch, R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood, 1995;86;3961-3969.
      Pubmed
    2. Gordan, LN, Sugrue, MW, Lynch, JW, et al. Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma, 2003;44;815-820.
      Pubmed
    3. DiPersio, JF, Micallef, IN, Stiff, PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol, 2009;27;4767-4773.
      Pubmed
    4. Olivieri, A, Marchetti, M, Lemoli, R, et al. Proposed definition of poor mobilizer in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo Italiano-Trapianto di Midollo Osseo. Bone Marrow Transplant, 2012;47;342-351.
      Pubmed
    5. Basak, GW, Jaksic, O, Koristek, Z, et al. Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization. Am J Hematol, 2011;86;550-553.
      Pubmed
    Blood Res
    Volume 59 2024

    Stats or Metrics

    Share this article on

    • line

    Blood Research

    pISSN 2287-979X
    eISSN 2288-0011
    qr-code Download